- Home
- BMRN vs ICLR Comparison
BMRN vs ICLR Comparison
Compare BMRN & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- ICLR
- Stock Information
- Founded
- BMRN 1996
- ICLR 1990
- Country
- BMRN United States
- ICLR Ireland
- Employees
- BMRN N/A
- ICLR N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BMRN Health Care
- ICLR Health Care
- Exchange
- BMRN Nasdaq
- ICLR Nasdaq
- Market Cap
- BMRN 13.7B
- ICLR 15.3B
- IPO Year
- BMRN 1999
- ICLR 1998
- Fundamental
- Price
- BMRN $71.44
- ICLR $179.07
- Analyst Decision
- BMRN Buy
- ICLR Buy
- Analyst Count
- BMRN 22
- ICLR 12
- Target Price
- BMRN $94.00
- ICLR $269.00
- AVG Volume (30 Days)
- BMRN 1.5M
- ICLR 933.3K
- Earning Date
- BMRN 04-23-2025
- ICLR 04-23-2025
- Dividend Yield
- BMRN N/A
- ICLR N/A
- EPS Growth
- BMRN 153.71
- ICLR 28.78
- EPS
- BMRN 2.21
- ICLR 9.53
- Revenue
- BMRN $2,853,915,000.00
- ICLR $8,281,675,999.00
- Revenue This Year
- BMRN $12.23
- ICLR $2.89
- Revenue Next Year
- BMRN $9.90
- ICLR $5.53
- P/E Ratio
- BMRN $32.37
- ICLR $18.90
- Revenue Growth
- BMRN 17.97
- ICLR 1.99
- 52 Week Low
- BMRN $60.63
- ICLR $174.93
- 52 Week High
- BMRN $94.85
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- BMRN 55.89
- ICLR 39.79
- Support Level
- BMRN $69.60
- ICLR $176.03
- Resistance Level
- BMRN $73.18
- ICLR $188.05
- Average True Range (ATR)
- BMRN 1.64
- ICLR 5.94
- MACD
- BMRN -0.15
- ICLR 0.02
- Stochastic Oscillator
- BMRN 63.45
- ICLR 31.25
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.